Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sexually Transmitted Infection (STI) Clear all
Terminated No phase listed Observational

Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus

NCT00321438
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
15
States / cities
Los Angeles, California • Tarzana, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 17, 2009 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 3 Interventional

A Trial to Test the Efficacy of a Tailored Intensive Smoking Cessation Intervention in Persons With HIV (PWHs)

NCT01106638
View directory record Official record
Conditions
Smoking, HIV Infections, AIDS
Interventions
Positively Smoke Free, Standard care
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 28, 2026, 5:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic

NCT07317687
View directory record Official record
Conditions
HIV Testing, HEPATITIS C (HCV), Syphilis, Hepatitis B Virus (HBV)
Interventions
Rapid Fingerstick Test, Blood Draw for lab test
Diagnostic Test
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Harpers Ferry, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

NCT00118898
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Youth Engagement Study: Intervention to Increase HIV Treatment Engagement and Adherence for Young People Living With HIV

NCT03665532
View directory record Official record
Conditions
HIV/AIDS
Interventions
Youth Engagement in Services
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
16 Years to 35 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

NCT04192487
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions
Crofelemer delayed-release tablets 125mg
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tustin, California • Stratford, Connecticut • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 28, 2026, 5:22 PM EDT
Withdrawn No phase listed Observational

Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults

NCT00736216
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
survey administration
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 24 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combinatorial Therapy to Induce an HIV Remission

NCT04357821
View directory record Official record
Conditions
HIV/AIDS
Interventions
Combination Intervention
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 67 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

An Extension of Protocol PRO 140_CD01 Study

NCT02355184
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus
Interventions
PRO 140 350mg weekly subcutaneous (SC) injection.
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 3 Interventional

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

NCT00002147
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal)
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 5:22 PM EDT
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

NCT03842436
View directory record Official record
Conditions
HIV/AIDS, Substance Use Disorders, Adherence, Medication
Interventions
Digital pill, Truvada
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boylston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 28, 2026, 5:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Screen Smart: Using Digital Health to Improve HIV Screening and Prevention

NCT06003192
View directory record Official record
Conditions
HIV Infections
Interventions
Universal Opt-out HIV Screening
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 21 Years
Enrollment
63,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
4
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile-Based Application "MyChoices"

NCT03179319
View directory record Official record
Conditions
HIV, Sexually Transmitted Diseases, Pre-exposure Prophylaxis, Risk Reduction
Interventions
MyChoices
Behavioral
Lead sponsor
Fenway Community Health
Other
Eligibility
15 Years to 24 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 28, 2026, 5:22 PM EDT
Terminated Phase 4 Interventional

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

NCT04249037
View directory record Official record
Conditions
HIV/AIDS
Interventions
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Standard initiation of antiretroviral therapy (ART)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

NCT02354937
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 30 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhanced SexHealth Intervention to Improve Adolescent Outcomes

NCT03341975
View directory record Official record
Conditions
Sexually Transmitted Diseases, Reproductive Behavior
Interventions
SexHealth
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 19 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 28, 2026, 5:22 PM EDT
Approved For Marketing No phase listed Expanded access

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

NCT00245739
View directory record Official record
Conditions
HIV Infections
Interventions
TMC-114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
202
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 199 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

NCT00001065
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Amphotericin B
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Jose, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 28, 2026, 5:22 PM EDT
Recruiting Phase 2 Interventional

Imaging Immune Activation in HIV by PET-MR

NCT03684655
View directory record Official record
Conditions
HIV Infections
Interventions
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Drug
Lead sponsor
CellSight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

NCT00098748
View directory record Official record
Conditions
HIV Infections
Interventions
Optimized Background Therapy (OBT), maraviroc (UK-427,857)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Sep 28, 2026, 5:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Finishing HIV Project

NCT06406049
View directory record Official record
Conditions
Hiv
Interventions
Control group-Standard Health Promotion, Social network intervention
Other · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 54 Years · Male only
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 28, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

NCT00085943
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
LEXIVA (GW433908), Ritonavir, KALETRA, EPIVIR, Ziagen, Abacavir/Lamivudine, Fosamprenavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 15, 2011 · Synced Sep 28, 2026, 5:22 PM EDT